{
    "clinical_study": {
        "@rank": "156600", 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine the preliminary efficacy and\n      tolerability of combining a selected dose of SC-48334 with low-dose AZT in the treatment of\n      symptomatic HIV+ patients with  200 to 500 CD4+ cells/mm3.\n\n      The secondary objective is to determine the pharmacokinetics and bioavailability of both\n      SC-48334 and AZT, when administered together, in symptomatic HIV+ patients with 200 -  500\n      CD4+ cells/mm3."
        }, 
        "brief_title": "Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Medications for the prophylaxis of opportunistic infections, such as:\n\n          -  Aerosolized pentamidine.\n\n          -  Trimethoprim/sulfamethoxazole.\n\n          -  Nystatin.\n\n          -  Clotrimazole.\n\n          -  Anti-mycobacterial agents.\n\n          -  Ganciclovir.\n\n          -  Topical acyclovir.\n\n        Patients must have the following:\n\n          -  CD4+ cells counts = or > 200 < 500 /cell mm3.\n\n          -  For purposes of inclusion the absolute CD4+ cell count must be = or > 200 < 500\n             cells/mm3 on the first sample and = or > 190 < 510 cells/mm3 on the second sample.\n\n          -  Have at least one of the following:\n\n          -  Oral candidiasis.\n\n          -  Herpes zoster during the last 3 years.\n\n          -  Oral hairy leukoplakia during the past three years.\n\n          -  Chronic ( > 30 day period), recurrent seborrheic dermatitis, or topical, pruritic\n             folliculitis (itchy bumps).\n\n          -  Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight.\n\n          -  Chronic fatigue present for the past 6 months, which has interfered with normal\n             activity at least 1 to 2 times per week.\n\n          -  HIV antibody positive as determined by federally licensed Enzyme-linked Immunosorbent\n             Assay (ELISA).\n\n          -  Documented, written informed consent must be obtained prior to admission to the\n             study.\n\n        Prior Medication:\n\n        Allowed for no more than 12 weeks prior to study entry:\n\n          -  Zidovudine (AZT).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Malignancies, with the exception of basal cell carcinoma.\n\n          -  Significant organ dysfunction.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  All anti-retroviral drugs with the exception of Zidovudine. Cancer chemotherapeutic\n             agents.\n\n          -  Anti-metabolites and alkylating agents.\n\n          -  All investigational non-FDA approved drugs.\n\n        Patients with the following are excluded:\n\n          -  Clinically significant diarrhea  (> 3 liquid stools per day for > 7 days) without\n             definable cause, within 6 months prior to enrollment).\n\n          -  Diarrhea, as above, with known, non-HIV related cause occurring within one month\n             prior to enrollment.\n\n          -  Meets CDC criteria for AIDS classification.\n\n          -  Chronic fever (> 38.5 C persisting for more than 14 consecutive days, or for more\n             than 15 days in any 30-day interval prior to study entry).\n\n          -  Malignancies, with the exception of basal cell carcinoma.\n\n          -  Significant organ dysfunction.\n\n          -  Known hypersensitivity to SC-48334 or related compounds.\n\n          -  History of lactose intolerance.\n\n        Prior Medication:\n\n        Excluded within 30 days of study entry:\n\n          -  Any investigational medication.\n\n          -  Treatment with a drug (other than Zidovudine) with anti-HIV activity.\n\n          -  Excluded for > 12 weeks prior to study entry:\n\n          -  Zidovudine (AZT).\n\n          -  Excluded within 90 days of study entry:\n\n          -  Ribavirin.\n\n          -  Excluded within 6 months of study entry:\n\n          -  Cancer chemotherapy.\n\n          -  Excluded:\n\n          -  Treatment with SC-48334.\n\n        Prior Treatment:\n\n        Excluded within 30 days of study entry:\n\n          -  Electron beam radiation.\n\n          -  Excluded within 6 months prior to study entry:\n\n          -  Required HIV-related blood transfusions.\n\n          -  Whole body radiation.\n\n        Current use of illicit substances; or current abuse of alcohol, the use of which would\n        limit compliance with the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "120", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001993", 
            "org_study_id": "057A", 
            "secondary_id": "NS8-90-02-004"
        }, 
        "intervention": [
            {
                "intervention_name": "Butyldeoxynojirimycin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Miglustat"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "331361013"
                    }, 
                    "name": "Univ of Miami School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Presbyterian - Saint Luke's Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Infectious Diseases Research Clinic / Indiana Univ Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "432101228"
                    }, 
                    "name": "Ohio State Univ Hosp Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Columbia", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29169"
                    }, 
                    "name": "Julio Arroyo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "981224304"
                    }, 
                    "name": "Univ of Washington"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "7905523", 
            "citation": "Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC Jr, Fass RJ, Fife KH, Powderly WG, Collier AC, Aspinall RL, et al. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr. 1994 Feb;7(2):139-47."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001993"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "G D Searle", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1992"
    }, 
    "geocoordinates": {
        "Infectious Diseases Research Clinic / Indiana Univ Hosp": "39.769 -86.158", 
        "Julio Arroyo": "33.993 -81.074", 
        "Ohio State Univ Hosp Clinic": "39.961 -82.999", 
        "Rush Presbyterian - Saint Luke's Med Ctr": "41.878 -87.63", 
        "Univ of Miami School of Medicine": "25.789 -80.226", 
        "Univ of Washington": "47.606 -122.332"
    }
}